Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study - Dent, R; Cortés, J; Pusztai, L (J Natl Cancer Inst, 2024)